Market Intelligence, Clinical Progress, and High-Purity Reagents for Breast Cancer Vaccine and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LALBA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LALBA Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (Native Glycosylation). |
View LALBA Products |
| Gene Delivery | LALBA Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and immunogenicity screening. |
View LALBA Products |
| Benchmark Ab | Anti-LALBA Biosimilar Recombinant positive control for IHC, ELISA, and flow cytometry assays. |
View LALBA Products |
| Validator | LALBA siRNA Set For target knockdown verification and specificity assays. |
View LALBA Products |
| Related Target A | B4GALT1 Heterodimerization partner with LALBA to form the functional lactose synthase complex. |
View B4GALT1 Products |
| Related Target B | SCGB2A2 Maternal breast-differentiation antigen co-expressed in breast carcinomas; key target for multi-antigen breast cancer vaccines. |
View SCGB2A2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational stability dependent on Calcium-binding | Calcium-loaded and Apo-state (calcium-free) formulation options; High Purity (>95%) verified by SDS-PAGE. |
| In vitro vaccine immunogenicity validation | Lentiviral vectors for stable LALBA expression in Antigen-Presenting Cells (APCs). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference controls. |
| False Positives | Target-specific siRNA pool included for gene-silencing specificity validation. |
Live LALBA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LALBA therapeutics is intensifying, with major players shifting focus from traditional mAbs to cancer vaccines and apoptotic protein-lipid complexes (such as HAMLET/BAMLET). As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting triple-negative breast cancer (TNBC) prevention and selective tumor-cell apoptosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cancer Vaccine | Anixa Biosciences, Cleveland Clinic | Triple-Negative Breast Cancer (TNBC) | Immunogenicity Assay (Need high-purity, sequence-verified antigen) |
| Protein-Lipid Complex (HAMLET) | HAMLET Pharma | Bladder Cancer, Solid Tumors | Apo-conformation validation (Need calcium-free recombinant protein) |
| Monoclonal Antibody / ADC | Academic Institutes | Lactating Breast Carcinomas | Internalization Assay (Need HEK293-expressed native protein) |